Duquesne Family Office LLC Increases Stock Holdings in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Duquesne Family Office LLC increased its stake in NewAmsterdam Pharma by 178.4%, acquiring an additional 512,825 shares, totaling 800,360 shares worth approximately $16.4 million.
• Several large investors, including Mirae Asset Global Investments and HB Wealth Management, have recently increased their holdings in NewAmsterdam Pharma, indicating strong institutional interest with 89.89% of the company's stock owned by institutional investors.
• NewAmsterdam Pharma's stock received positive analyst ratings, with a consensus price target of $41.55 and multiple brokerages issuing "buy" and "outperform" ratings as of recent reports.

Duquesne Family Office LLC increased its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 178.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 800,360 shares of the company's stock after buying an additional 512,825 shares during the period. Duquesne Family Office LLC owned about 0.73% of NewAmsterdam Pharma worth $16,383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NAMS. Deerfield Management Company L.P. Series C lifted its position in shares of NewAmsterdam Pharma by 378.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after buying an additional 3,412,590 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in shares of NewAmsterdam Pharma by 23.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after buying an additional 3,061,224 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock valued at $59,499,000 after buying an additional 2,222,900 shares in the last quarter. RA Capital Management L.P. lifted its position in shares of NewAmsterdam Pharma by 14.6% during the 1st quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock valued at $207,544,000 after buying an additional 1,293,938 shares in the last quarter. Finally, Woodline Partners LP lifted its position in shares of NewAmsterdam Pharma by 108.7% during the 4th quarter. Woodline Partners LP now owns 2,430,782 shares of the company's stock valued at $62,471,000 after buying an additional 1,266,105 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company's stock.

Insiders Place Their Bets

In related news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the firm's stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $24.29, for a total transaction of $1,214,500.00. Following the completion of the sale, the insider directly owned 119,302 shares of the company's stock, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Douglas F. Kling sold 51,043 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $21.10, for a total value of $1,077,007.30. Following the sale, the chief operating officer directly owned 44,000 shares of the company's stock, valued at $928,400. The trade was a 53.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 12,835 shares of company stock valued at $248,134 and sold 274,954 shares valued at $5,899,406. 20.84% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NAMS. Royal Bank Of Canada increased their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research report on Thursday, August 7th. Cantor Fitzgerald began coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price objective for the company. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, July 5th. Citigroup began coverage on NewAmsterdam Pharma in a research note on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price objective for the company. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They issued a "neutral" rating and a $27.00 price objective for the company. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, NewAmsterdam Pharma currently has a consensus rating of "Moderate Buy" and an average price target of $41.55.

NewAmsterdam Pharma Stock Up 5.2%

Shares of NAMS traded up $1.34 during midday trading on Friday, reaching $27.00. The company had a trading volume of 1,570,503 shares, compared to its average volume of 806,032. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29. The stock has a market cap of $3.04 billion, a PE ratio of -16.67 and a beta of -0.01. The firm has a 50 day simple moving average of $22.98 and a 200-day simple moving average of $20.56.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. As a group, sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.